Blood test could revolutionize childhood cancer monitoring

NCT ID NCT07356882

First seen Jan 22, 2026 · Last updated Jun 19, 2026 · Updated 23 times

Summary

This study is testing whether a simple blood test (called a liquid biopsy) can better predict relapse in children and young adults with classical Hodgkin lymphoma. Researchers will track 400 participants under age 25, comparing the test's accuracy to standard PET/CT scans. The goal is to improve early detection of high-risk patients and reduce treatment burden for low-risk patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pediatric Hematology and Oncology Department

    RECRUITING

    Paris, 75012, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple blood test that helps doctors personalize treatment for young Hodgkin lymphoma patients, catching relapses earlier and reducing unnecessary side effects.

What could go wrong

This is an observational study, not a treatment trial. The blood test may not prove accurate enough to replace current imaging methods, and results may take years to confirm.

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.